Stöver Lehmann Consulting

1. Stöver Lehmann Consulting By Manon Stöver Matthieu Lehmann Lausanne, June 23rd 2006

2. Agenda • Who are we ? • Why are we here today ? • What has been done until today? • What can be achieved and how? Stöver Lehmann Consulting

3. SLC – Team presentation • Manon Stöver • Co-founder • Expertise in investment within the Petroleum Industry • Matthieu Lehmann • Co-founder • Expertise in Biotechnologies and Process Development Stöver Lehmann Consulting

4. SLC - Philosophy • Our orientation is to raise funds for refreshing and interesting research and development • Our vision is to support ideas with huge potential for humanity • We are looking for revolution more than evolution Stöver Lehmann Consulting

5. SLC – Past Successes • SLC’s past successes in raising funds are in the field of research and development: • BioXell (Cancer therapy) • 7TM Pharma (Virology) • H2FUEL (hydrogen engine) • HydroNEXT (biofuel cell) Stöver Lehmann Consulting

6. Dr. de Grey’s presentation • Engineering background from computer sciences • Previous work in bioinformatics • Current research in biogerontology • His vision: Reengineering the approach of how to cure aging Stöver Lehmann Consulting

7. Gerontology Engineering Geriatrics Metabolism Damage Pathology What is Unlimited Life? • A research institute in biogerontology • A concept: Curing aging • The final mission of UL is to provide people with medecines to cure aging Stöver Lehmann Consulting

8. More about Unlimited Life • Home institution for research is Cambridge • Research is highly potential for several breakthroughs : ‘We are already on the road, it’s definitely more than a simple concept !’ • Absolutely refreshing approach of anti-aging process: start at the roots of the process • At the beginning of something revolutionary Stöver Lehmann Consulting

9. The 7 deadly things principle • Basics of Dr. de Grey research • Damages rising with age • Cell loss, cell atrophy • Nuclear [epi]mutations (only cancer matters) • Mutant mitochondria • Death-resistant cells • Extracellular crosslinks • Extracellular junk • Intracellular junk Stöver Lehmann Consulting

10. Today’s Focus • Advise to improve funding of Unlimited Life research Why are we concerned ? • We believe in our customer competencies • We may change the world • Aging is the most fatal and the first cause of death on Earth • Life is a gift, we must fight to keep it as hard as we fight for our freedom Stöver Lehmann Consulting

11. Competitive Anti-Aging Researches • Current technologies to slow the aging process • Cryonic therapy • Chemical drugs (DHEA) • Medicines based on proteins • Plastic surgery • Vitamins and food supplements Stöver Lehmann Consulting

12. Results for current Anti-Aging • Results obtained from research • Slowing down the process of aging • Mask the external signs of aging • Small improvement on the origin of aging process • None of these technology treated aging from its roots • NB! These technologies are not competitive with the results of Dr. de Grey’s research Stöver Lehmann Consulting

13. Origin of previous raised funds • Past funds • Winning the Mprize: donations for continuing research • Expenses contributions • Donation of Air miles • Who are these investors ? • Individuals • Foundations Stöver Lehmann Consulting

14. Money raised from these funds • Funds raised • Mprize: $ 3.5 million • Donations: $ 218’005 • Cost expenses: $ 89’756 • Air miles: 360’374 miles Good starting point but obviously not enough ! Stöver Lehmann Consulting

15. Dr. de Grey’s request for funding • Dr. de Grey objectives: • $100M/year of funding for the next 10 years • Creating research institutes all over the world • Investors are not to draw any direct benefit from providing funding Stöver Lehmann Consulting

16. Possible solutions • Organizational improvements • Promotion improvements • Improvement of current funding ways • New funding ways Stöver Lehmann Consulting

17. Organizational improvements • Organizational aspect • Define milestones/targets • Build a team • Find a ‘face’ for funding leader Stöver Lehmann Consulting

18. Promotion improvements • Generate publicity • Newspapers • Broadcasting of documentaries • Universities • Advertisements • Exhibition • Nobel price for medicine Stöver Lehmann Consulting

19. Improvement of current funding ways • Donations • Other foundations • Individuals • Air miles Stöver Lehmann Consulting

20. Foundations and Individuals • Aim at other foundations: • AIDS association • Cancer therapy association • Arthritis Foundation • Biological Trust • Convince individuals: • Wealthy philanthropic people Stöver Lehmann Consulting

21. Airmiles Change the law • Airline companies might write off their airmiles older than 20y to foundations • Opportunity to raise billions of airmiles • Very convenient for both parties Stöver Lehmann Consulting

22. New funding ways • Business Angels • Open source research • Partnerships • VCs Stöver Lehmann Consulting

23. Business angels • With certain characteristics: • High personal interest in the research • Diversifying his/her investments • Maybe (s)he will give a billion • Examples • Donald Trump • Hugh Hefner • Bill Gates • Larry Ellison Stöver Lehmann Consulting

24. Larry Ellison • Founder of Oracle • Almost as wealthy as Bill Gates • Human benefactor • What is more prestigious than investing in first cause of death Stöver Lehmann Consulting

25. Open source • No profits involvement • Access to a huge community • Low and shared cost • Increase in time efficiency and productivity • High demanding process from a controlling aspect Stöver Lehmann Consulting

26. Open source in our case • Applicable on secondary level of research • Set up an association with confidential agreement • Create different virtual institutes around the world Stöver Lehmann Consulting

27. Partnership • Partners • Cooperation in research; such as Cryogenics • Set up subsidiaries with pharmaceuticals • VCs with pharmaceuticals in the portfolio • Business angels with certain interests • To attract partners: certain level of leverage needed • Define milestones/targets • Create a source of revenues Stöver Lehmann Consulting

28. Venture Capitalist • Involvement in the management and the ownership • Huge amount money can be brought on the table • Examples • Cardinal Partners • Polaris Venture Partners • Techno Venture Management • Novartis Bioventures Fund • Cargill Ventures Three Arch Partners Stöver Lehmann Consulting

29. Funding schedule First two years • Research set up • Define milestones/targets for third parties • Alliances with anti-aging clinics to set up globally research institutes at universities • Create a team • Use of benefits of an open source research • Funds • Foundations and prices • Business Angels • Adjust budget Stöver Lehmann Consulting

30. Funding schedule Next three years • Involvement of VCs • Creating revenues (seminars, meetings, publishing books, magazines) • Partnership with pharmaceutical companies regarding first mover advantage for commercial use Stöver Lehmann Consulting

31. Financial Scheme - Sources Stöver Lehmann Consulting

32. Financial scheme - Uses Stöver Lehmann Consulting

33. Conclusion • We have investigated possibilities for funding • within the requests • outside the requests • Who dares wins… Stöver Lehmann Consulting

34. Thank for your attention Manon Stöver: manonstover@gmail.com Matthieu Lehmann matthieu.lehmann@epfl.ch